{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:55:14Z","timestamp":1789610114973,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005909","name":"Nemzeti Fejleszt\u00e9si Miniszt\u00e9rium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005909","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ijantimicag.2022.106543","type":"journal-article","created":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T01:07:49Z","timestamp":1644109669000},"page":"106543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model"],"prefix":"10.1016","volume":"59","author":[{"given":"Frederik Bo\u00ebtius","family":"Hertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-6761","authenticated-orcid":false,"given":"Minna Rud","family":"Andreasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine Radmer","family":"Almind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7912-1985","authenticated-orcid":false,"given":"Karen Leth","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5471-711X","authenticated-orcid":false,"given":"Katrine Hartung","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6642-7424","authenticated-orcid":false,"given":"Lotte","family":"Jelsbak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Frimodt-M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7767-305X","authenticated-orcid":false,"given":"Kristian","family":"Sch\u00f8nning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106543_bib0001","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.23.46.1800393","article-title":"Antimicrobial use in European acute care hospitals: Results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017","volume":"23","author":"Plachouras","year":"2018","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0002","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/jac\/dkx494","article-title":"Antimicrobial usage in German acute care hospitals: Results of the third national point prevalence survey and comparison with previous national point prevalence surveys","volume":"73","author":"Aghdassi","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0003","unstructured":"DANMAP 2020 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animlas, food and humans in Denmark. ISSN 1600-2032 n.d. https:\/\/www.danmap.org\/reports\/2020 [accessed 3 January 2022]."},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0004","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy300","article-title":"Epidemiology of bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae that are piperacillin-tazobactam-nonsusceptible but ceftriaxone-susceptible","volume":"5","author":"Baker","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0005","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1093\/jac\/dkz349","article-title":"Resistance to piperacillin\/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1","volume":"74","author":"Hansen","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0006","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1128\/AAC.01208-16","article-title":"In vitro-in vivo discordance with humanized piperacillin-tazobactam exposures against piperacillin-tazobactam-resistant\/pan-\u03b2-lactam-susceptible Escherichia coli","volume":"60","author":"Monogue","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105885","article-title":"Piperacillin-tazobactam-resistant\/third-generation cephalosporin-susceptible Escherichia coli and Klebsiella pneumoniae isolates: Resistance mechanisms and in vitro-in vivo discordance","volume":"55","author":"Abdelraouf","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0008","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.46.12.4035-4037.2002","article-title":"Promoters P3, Pa\/Pb, P4, and P5 upstream from blaTEM genes and their relationship to \u03b2-lactam resistance","volume":"46","author":"Lartigue","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0009","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/AAC.01752-10","article-title":"In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse Gram-negative organisms","volume":"56","author":"Bulik","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0010","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1128\/AAC.01347-15","article-title":"Population pharmacokinetics of piperacillin in the early phase of septic shock: Does standard dosing result in therapeutic plasma concentrations?","volume":"59","author":"\u00d6brink-Hansen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0011","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/jac\/31.suppl_D.55","article-title":"The mouse peritonitis model: present and future use","volume":"31","author":"Frimodt-M\u00f8ller","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.ijantimicag.2022.106543_bib0012","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.02190-12","article-title":"Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model","volume":"57","author":"Docobo-P\u00e9rez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0013","doi-asserted-by":"crossref","first-page":"a016592","DOI":"10.1101\/cshperspect.a016592","article-title":"Mechanisms of gene duplication and amplification","volume":"7","author":"Reams","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0014","doi-asserted-by":"crossref","first-page":"e00583","DOI":"10.1128\/mBio.00583-18","article-title":"Extensive gene amplification as a mechanism for piperacillin-tazobactam resistance in Escherichia coli","volume":"9","author":"Schechter","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0015","article-title":"Single-molecule nanopore sequencing reveals extreme target copy number heterogeneity in arylomycin-resistant mutants","volume":"118","author":"Girgis","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2022.106543_bib0016","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:36:26Z","timestamp":1767137786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0924857922000310"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106543","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106543"}}